Objective:To study the effect of minimally invasive intracranial hematoma drainage on inflammatory factors, serum ferritin and serum P substance in patients with hypertensive cerebral hemorrhage.Methods:92 cases of hy...Objective:To study the effect of minimally invasive intracranial hematoma drainage on inflammatory factors, serum ferritin and serum P substance in patients with hypertensive cerebral hemorrhage.Methods:92 cases of hypertensive cerebral hemorrhage patients in our hospital were selected and randomly divided into 2 groups: minimally invasive group (51 cases) and routine group (41 cases). Minimally invasive intracranial hematoma drainage was performed on the minimally invasive group. Bone flap decompression or small bone window craniotomy were used in the routine group. Tumor necrosis factorα (TNF-α), interleukin-6 (IL-6), high sensitive C reactive protein (hs-CRP) and serum protein (SF), serum substance P (SP) in the 2 groups were detected before treatment and 2 weeks after treatment.Results: The comparison of TNF-α, IL-6, hs-CRP, SP, and SF in the two groups before treatment was not statistically significant (P>0.05). TNF-α, IL-6, hs-CRP and SF in both groups after treatment significantly decreased, compared with that before treatment (P<0.01,P<0.05). TNF-α, IL-6, and SF in minimally invasive group decreased more significantly than that in routine group (P<0.01);The comparison of SP in the two groups after treatment significantly increased compared with that before treatment (P<0.01,P<0.05). SP in minimally invasive group increased more significantly than that in routine group (P<0.05).Conclusions:Compared with bone flap decompression or small bone window craniotomy, minimally invasive intracranial hematoma drainage can inhibit inflammatory reaction, reduce the degree of nerve damage and alleviate clinical symptoms more effectively.展开更多
Objective:To explore the therapeutic effect of minimally invasive intracranial hematoma evacuation in the treatment of hypertensive cerebral hemorrhage and the value of dynamic TCD monitoring in predicting the neurolo...Objective:To explore the therapeutic effect of minimally invasive intracranial hematoma evacuation in the treatment of hypertensive cerebral hemorrhage and the value of dynamic TCD monitoring in predicting the neurological function recovery.Methods: A total of 70 patients with hypertensive cerebral hemorrhage who were admitted in our hospital were included in the study and divided into the minimally invasive group and conservative group with 35 cases in each group according to different treatment protocols. The patients in the two groups were given drug conservative treatments. On this basis, the patients in the minimally invasive group were given urokinase in combined with minimally invasive hematoma puncture with YL-1 type needle. TCD was performed before treatment, 1 d, 5 d, 10 d, and 21 d after treatment. The hematoma and edema volume was calculated. NIHSS was used to evaluate the neurological function recovery.Results: Vs, Vd, and Vm after treatment in the minimally invasive group were significantly elevated, while PI was significantly reduced. Vs, Vd, and Vm after treatment in the conservative group were reduced first and elevated later, while PI was elevated first and reduced later, and reached the lowest/peak 10d after treatment. Vs, Vd, and Vm 5 d, 10 d, and 21 d after treatment in the minimally invasive group were significantly higher than those in the conservative group, while PI was significantly lower than that in the conservative group. The hematoma and edema volume after treatment in the two groups was significantly reduced. The hematoma and edema volume at each timing point was significantly lower than that in the conservative group. NIHSS score after treatment in the minimally invasive group was significantly reduced. NIHSS score in the conservative group was elevated first and reduced later, reached the peak 10d after treatment, and at each timing point was higher than that in the minimally invasive group.Conclusions:The early minimally invasive operation can significantly improve the hematoma adjacent blood flow volume in patients with hypertensive cerebral hemorrhage, and contribute to the neurological function recovery. TCD not only can be applied in the dynamic monitoring of cerebral blood flow volume in patients with hypertensive cerebral hemorrhage, but also has a certain value in evaluating the prognosis of neurological function.展开更多
目的:系统评价颅内血肿微创清除手术联合脑血疏口服液治疗自发性脑出血的疗效及安全性。方法:计算机检索从建库至2023年6月收录于中国期刊全文数据库(China National Knowledge Infrastructure,CNKI)、维普中文科技期刊数据库(VIP Chine...目的:系统评价颅内血肿微创清除手术联合脑血疏口服液治疗自发性脑出血的疗效及安全性。方法:计算机检索从建库至2023年6月收录于中国期刊全文数据库(China National Knowledge Infrastructure,CNKI)、维普中文科技期刊数据库(VIP Chinese science and technology journal database,VIP)、万方数据库、中国生物医学文献数据库(The Chinese biomedical literature database,CBM)、PubMed、Embase、the Cochrane Library等中英文数据库,结合纳入与排除标准筛选出所有颅内血肿微创清除手术联合脑血疏口服液治疗自发性脑出血的临床随机对照试验,根据Cochrane系统评价手册对纳入研究进行偏倚风险评价,运用Revman5.4软件进行Meta分析,最后采用GRADE系统对结局指标进行证据质量评价。结果:共纳入9项研究,总样本量739例。其中,对照组371例,试验组368例。Meta分析结果显示,与血肿微创清除后仅予常规西医治疗相比,联合应用脑血疏口服液能够提高自发性脑出血患者临床治疗的总有效率[OR=5.47,95%CI=2.28,13.09,P=0.0001],在降低患者美国国立卫生研究所卒中量表评分[MD=−3.42,95%CI=−4.97,−1.87,P<0.0001]和中国脑卒中患者神经功能缺损程度评分[MD=−2.30,95%CI=−3.01,−1.58,P<0.00001],提高患者格拉斯哥昏迷量表(Glasgow coma scale,GCS)评分[MD=1.51,95%CI=1.13,1.89,P<0.00001]和Barthel指数(Barthel index,BI)评分[MD=6.88,95%CI=4.49,9.27,P<0.00001],降低血清S100蛋白[MD=−0.02,95%CI=−0.03,−0.02,P<0.00001]和水通道蛋白4水平[MD=−0.02,95%CI=−0.03,−0.01,P=0.002]方面均具有明显优势。安全性方面,所纳研究均无严重不良反应;2项研究报告有恶心、腹胀、腹泻的胃肠道不适症状,其余研究未报告不良反应发生。结论:现有证据表明,颅内血肿微创清除手术联合脑血疏口服液治疗自发性脑出血疗效确切,能够明显减轻患者神经功能缺损和意识障碍程度,提高患者日常生活能力,改善患者生活质量,且具有一定的安全性。展开更多
目的分析高血压性脑出血(HICH)患者微创颅内血肿清除术后发生再出血的相关影响因素。方法回顾性分析80例行微创颅内血肿清除术的HICH患者的临床资料,统计再出血发生率,采用单因素和多因素分析探讨术后再出血的危险因素。结果80例HICH患...目的分析高血压性脑出血(HICH)患者微创颅内血肿清除术后发生再出血的相关影响因素。方法回顾性分析80例行微创颅内血肿清除术的HICH患者的临床资料,统计再出血发生率,采用单因素和多因素分析探讨术后再出血的危险因素。结果80例HICH患者术后再出血发生率为16.25%。单因素和多因素Logistic回归分析显示,术前舒张压>120 mm Hg、术前收缩压>200 mm Hg、术前GCS评分≤8分、合并糖尿病、术前血肿量≥60 mL是HICH患者微创颅内血肿清除术后发生再出血的独立危险因素(P<0.05)。结论术前舒张压>120 mm Hg、术前收缩压>200 mm Hg、术前GCS评分≤8分、合并糖尿病、术前血肿量≥60 mL是HICH患者微创颅内血肿清除术后发生再出血的独立危险因素。展开更多
文摘Objective:To study the effect of minimally invasive intracranial hematoma drainage on inflammatory factors, serum ferritin and serum P substance in patients with hypertensive cerebral hemorrhage.Methods:92 cases of hypertensive cerebral hemorrhage patients in our hospital were selected and randomly divided into 2 groups: minimally invasive group (51 cases) and routine group (41 cases). Minimally invasive intracranial hematoma drainage was performed on the minimally invasive group. Bone flap decompression or small bone window craniotomy were used in the routine group. Tumor necrosis factorα (TNF-α), interleukin-6 (IL-6), high sensitive C reactive protein (hs-CRP) and serum protein (SF), serum substance P (SP) in the 2 groups were detected before treatment and 2 weeks after treatment.Results: The comparison of TNF-α, IL-6, hs-CRP, SP, and SF in the two groups before treatment was not statistically significant (P>0.05). TNF-α, IL-6, hs-CRP and SF in both groups after treatment significantly decreased, compared with that before treatment (P<0.01,P<0.05). TNF-α, IL-6, and SF in minimally invasive group decreased more significantly than that in routine group (P<0.01);The comparison of SP in the two groups after treatment significantly increased compared with that before treatment (P<0.01,P<0.05). SP in minimally invasive group increased more significantly than that in routine group (P<0.05).Conclusions:Compared with bone flap decompression or small bone window craniotomy, minimally invasive intracranial hematoma drainage can inhibit inflammatory reaction, reduce the degree of nerve damage and alleviate clinical symptoms more effectively.
文摘Objective:To explore the therapeutic effect of minimally invasive intracranial hematoma evacuation in the treatment of hypertensive cerebral hemorrhage and the value of dynamic TCD monitoring in predicting the neurological function recovery.Methods: A total of 70 patients with hypertensive cerebral hemorrhage who were admitted in our hospital were included in the study and divided into the minimally invasive group and conservative group with 35 cases in each group according to different treatment protocols. The patients in the two groups were given drug conservative treatments. On this basis, the patients in the minimally invasive group were given urokinase in combined with minimally invasive hematoma puncture with YL-1 type needle. TCD was performed before treatment, 1 d, 5 d, 10 d, and 21 d after treatment. The hematoma and edema volume was calculated. NIHSS was used to evaluate the neurological function recovery.Results: Vs, Vd, and Vm after treatment in the minimally invasive group were significantly elevated, while PI was significantly reduced. Vs, Vd, and Vm after treatment in the conservative group were reduced first and elevated later, while PI was elevated first and reduced later, and reached the lowest/peak 10d after treatment. Vs, Vd, and Vm 5 d, 10 d, and 21 d after treatment in the minimally invasive group were significantly higher than those in the conservative group, while PI was significantly lower than that in the conservative group. The hematoma and edema volume after treatment in the two groups was significantly reduced. The hematoma and edema volume at each timing point was significantly lower than that in the conservative group. NIHSS score after treatment in the minimally invasive group was significantly reduced. NIHSS score in the conservative group was elevated first and reduced later, reached the peak 10d after treatment, and at each timing point was higher than that in the minimally invasive group.Conclusions:The early minimally invasive operation can significantly improve the hematoma adjacent blood flow volume in patients with hypertensive cerebral hemorrhage, and contribute to the neurological function recovery. TCD not only can be applied in the dynamic monitoring of cerebral blood flow volume in patients with hypertensive cerebral hemorrhage, but also has a certain value in evaluating the prognosis of neurological function.
文摘目的:系统评价颅内血肿微创清除手术联合脑血疏口服液治疗自发性脑出血的疗效及安全性。方法:计算机检索从建库至2023年6月收录于中国期刊全文数据库(China National Knowledge Infrastructure,CNKI)、维普中文科技期刊数据库(VIP Chinese science and technology journal database,VIP)、万方数据库、中国生物医学文献数据库(The Chinese biomedical literature database,CBM)、PubMed、Embase、the Cochrane Library等中英文数据库,结合纳入与排除标准筛选出所有颅内血肿微创清除手术联合脑血疏口服液治疗自发性脑出血的临床随机对照试验,根据Cochrane系统评价手册对纳入研究进行偏倚风险评价,运用Revman5.4软件进行Meta分析,最后采用GRADE系统对结局指标进行证据质量评价。结果:共纳入9项研究,总样本量739例。其中,对照组371例,试验组368例。Meta分析结果显示,与血肿微创清除后仅予常规西医治疗相比,联合应用脑血疏口服液能够提高自发性脑出血患者临床治疗的总有效率[OR=5.47,95%CI=2.28,13.09,P=0.0001],在降低患者美国国立卫生研究所卒中量表评分[MD=−3.42,95%CI=−4.97,−1.87,P<0.0001]和中国脑卒中患者神经功能缺损程度评分[MD=−2.30,95%CI=−3.01,−1.58,P<0.00001],提高患者格拉斯哥昏迷量表(Glasgow coma scale,GCS)评分[MD=1.51,95%CI=1.13,1.89,P<0.00001]和Barthel指数(Barthel index,BI)评分[MD=6.88,95%CI=4.49,9.27,P<0.00001],降低血清S100蛋白[MD=−0.02,95%CI=−0.03,−0.02,P<0.00001]和水通道蛋白4水平[MD=−0.02,95%CI=−0.03,−0.01,P=0.002]方面均具有明显优势。安全性方面,所纳研究均无严重不良反应;2项研究报告有恶心、腹胀、腹泻的胃肠道不适症状,其余研究未报告不良反应发生。结论:现有证据表明,颅内血肿微创清除手术联合脑血疏口服液治疗自发性脑出血疗效确切,能够明显减轻患者神经功能缺损和意识障碍程度,提高患者日常生活能力,改善患者生活质量,且具有一定的安全性。
文摘目的分析高血压性脑出血(HICH)患者微创颅内血肿清除术后发生再出血的相关影响因素。方法回顾性分析80例行微创颅内血肿清除术的HICH患者的临床资料,统计再出血发生率,采用单因素和多因素分析探讨术后再出血的危险因素。结果80例HICH患者术后再出血发生率为16.25%。单因素和多因素Logistic回归分析显示,术前舒张压>120 mm Hg、术前收缩压>200 mm Hg、术前GCS评分≤8分、合并糖尿病、术前血肿量≥60 mL是HICH患者微创颅内血肿清除术后发生再出血的独立危险因素(P<0.05)。结论术前舒张压>120 mm Hg、术前收缩压>200 mm Hg、术前GCS评分≤8分、合并糖尿病、术前血肿量≥60 mL是HICH患者微创颅内血肿清除术后发生再出血的独立危险因素。
